Future growth expectations in earnings/operating earnings/profits/EPS?

Navin Fluorine targets to maintain an Operating EBITDA margin around 25% (between 23%-27%) for FY '26, striving for stability amid market uncertainties. CDMO business aims for $100 million revenue by FY '27, supported equally by existing contracts, new MSAs, and base business. The fluoro specialty project (INR540 crores capex) is ramping up, expected to reach 50%-55% utilization by end FY '26, contributing to earnings growth. Capital expenditure guidance for FY '26 is INR 500-600 crores, supporting capacity expansion and cGMP4 commissioning. Depreciation and finance costs are increasing due to

Current/ Expected Orderbook/ Pending Orders?

Navin Fluorine is working on 10 to 15 commercial or late-stage products in the CDMO vertical with growth potential. A commercial order from a U.S. major is expected for delivery in FY '26, following a successful scale-up order delivered in Q4 FY '25. Multiple inquiries for R32 capacity came much before the capacity became operational, indicating strong demand. Discussions with global majors for strategic partnerships on new capacities are ongoing. The initial production capacity for Opteon is sufficient to support several field trials to accelerate market adoption. The partnership with Chemour

Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the provided transcript. The company emphasizes a strong financial position with a net debt-to-equity of 0.37 as of March 31, 2025. Capex plans for FY '26 are guided between INR 500-600 crores, funded comfortably through the balance sheet and cash flows. Interest costs are expected to reduce as debt is paid down, indicating no immediate need for more borrowing. The $14 million capex for the Chemours tie-up includes a $5 million contribution by Chemours themselves, reflecting a partnership rather than Navin alone funding. Mana

Future growth expectations in sales/revenue/volumes?

Navin Fluorine aims to grow its CDMO business to $100 million revenue by FY '27, supported equally by existing contracts, new MSAs, and base business. The company sees strong growth in the liquid cooling market, expected to grow from $0.5 billion today to $3 billion by 2035, including two-phase immersion cooling liquids. Fluoro specialty project (INR 540 crores capex) is ramping up with 50-55% utilization expected by end FY '26, contributing to revenue growth. New capacity for R32 refrigerant is servicing global markets, with healthy pricing and strategic partnerships in discussion. cGMP4 phas

IN US

Sale is live|00:00:00left today

Navin Fluorine International LtdQ1 FY25Chemicals & Petrochemicals

Navin Fluorine International Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹7,303P/E: 53.7Market Cap: ₹35.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Navin Fluorine aims to grow its CDMO business to $100 million revenue by FY '27, supported equally by existing contracts, new MSAs, and base business.
→The company sees strong growth in the liquid cooling market, expected to grow from $0.5 billion today to $3 billion by 2035, including two-phase immersion cooling liquids.
→Fluoro specialty project (INR 540 crores capex) is ramping up with 50-55% utilization expected by end FY '26, contributing to revenue growth.
→New capacity for R32 refrigerant is servicing global markets, with healthy pricing and strategic partnerships in discussion.
→cGMP4 phase 1 capex (INR 160 crores) for CDMO business is on track for end of Q3 FY '26 commissioning, enabling further capacity expansion.
→Overall revenue growth driven by product diversification, capacity expansions, and increasing repeat orders in CDMO and specialty chemicals.

Margin guidance

Category 3

→Navin Fluorine targets to maintain an Operating EBITDA margin around 25% (between 23%-27%) for FY '26, striving for stability amid market uncertainties.
→CDMO business aims for $100 million revenue by FY '27, supported equally by existing contracts, new MSAs, and base business.
→The fluoro specialty project (INR540 crores capex) is ramping up, expected to reach 50%-55% utilization by end FY '26, contributing to earnings growth.
→Capital expenditure guidance for FY '26 is INR 500-600 crores, supporting capacity expansion and cGMP4 commissioning.
→Depreciation and finance costs are increasing due to recent capex but expected to stabilize/decrease as debt reduces.
→Continued strategic partnerships (e.g., with Chemours) are expected to drive revenue in advanced materials, further boosting profits and EPS.
→The company emphasizes disciplined project execution and expects gradual but consistent growth over the next 2 years.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any new fundraising through debt or equity in the provided transcript.
→The company emphasizes a strong financial position with a net debt-to-equity of 0.37 as of March 31, 2025.
→Capex plans for FY '26 are guided between INR 500-600 crores, funded comfortably through the balance sheet and cash flows.
→Interest costs are expected to reduce as debt is paid down, indicating no immediate need for more borrowing.
→The $14 million capex for the Chemours tie-up includes a $5 million contribution by Chemours themselves, reflecting a partnership rather than Navin alone funding.
→Management underscores disciplined capital investments within a well-defined financial structure and strong balance sheet.

Order book

→Navin Fluorine is working on 10 to 15 commercial or late-stage products in the CDMO vertical with growth potential.
→A commercial order from a U.S. major is expected for delivery in FY '26, following a successful scale-up order delivered in Q4 FY '25.
→Multiple inquiries for R32 capacity came much before the capacity became operational, indicating strong demand.
→Discussions with global majors for strategic partnerships on new capacities are ongoing.
→The initial production capacity for Opteon is sufficient to support several field trials to accelerate market adoption.
→The partnership with Chemours is aimed at scaling production as adoption of two-phase immersion cooling liquids grows.
→Overall, order inflow is robust across product lines and geographies, supporting growth targets into FY '26 and FY '27.

Capex plans

Yes

- Fluoro Specialty Project: Commercial production started Dec 2024 at Dahej facility; ramping up well. - Surat Expansion: INR 30 crores expansion initiated dispatches from Feb 2025. - cGMP4 Capex: INR 288 crores planned; Phase 1 (INR 160 crores) on track for commissioning by Q3 FY '26. - Opteon Project with Chemours: $14 million capex; initial capacity set up to accelerate market adoption, with potential for further capacity expansion. - CDMO Business: Strategic investment with capex run rate approx. INR 500-600 crores for FY '26. - Margins targeted at around 25% with ongoing efforts. - Partnership Importance: Chemours' $5 million co-investment symbolic for partnership and strategy, despite Navin's capacity to fully fund. - Growth Focus: Continuing targeted capital investments aligned with market evolution and strategic priorities. Overall, investments focus on capacity ramp-up, new technologies (advanced materials like immersion cooling liquids), and scaling CDMO capabilities.

How does Navin Fluorine International Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Navin Fluorine International Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Navin Fluorine International Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio